Intrahepatic cholestasis is a condition where bile flow becomes impaired inside the liver itself, causing bile acids to build up in the bloodstream instead of draining into the intestines. It is most commonly encountered during pregnancy, but it can also be triggered by medications, genetic conditions, or liver disease. The hallmark symptom is intense itching, often without a visible rash, and blood tests typically show elevated bile acid levels above 10 micromol/L.
How Bile Flow Gets Disrupted
Your liver cells produce bile, a digestive fluid that helps break down fats and clear waste products from the body. Normally, specialized transport proteins on the surface of liver cells pump bile acids, cholesterol, and other compounds out into tiny channels called bile canaliculi, which drain into larger bile ducts and eventually reach the intestines.
In intrahepatic cholestasis, the problem occurs at the level of these transport proteins or the liver cells themselves. When these pumps malfunction or become overwhelmed, bile acids accumulate inside liver cells and spill into the bloodstream. As a protective response, the liver tries to reroute bile acids out through an alternative exit on the opposite side of the cell, but this backup system has limits. The result is a rising concentration of bile acids in your blood, which is responsible for the characteristic itching and can be measured with a simple blood test.
This distinguishes intrahepatic cholestasis from extrahepatic cholestasis, where the blockage is physical, such as a gallstone or tumor pressing on the bile ducts outside the liver. An abdominal ultrasound can usually tell the two apart: in intrahepatic cholestasis the bile ducts look normal, while in extrahepatic cholestasis they appear dilated or swollen.
Common Causes
The most well-known form is intrahepatic cholestasis of pregnancy (ICP), which typically develops in the late second or third trimester. The cause is multifactorial. Rising estrogen levels, which peak late in pregnancy, appear to impair bile transport in women who are genetically susceptible. Progesterone plays a role too: its breakdown products interfere with the liver’s main bile acid receptor, further disrupting the transport system. ICP is more common in pregnancies with twins or after ovarian hyperstimulation, both situations where hormone levels run especially high.
Medications are another major trigger. Antibiotics, particularly amoxicillin/clavulanate, are the most common drug category causing cholestatic liver injury. Oral contraceptives and anabolic steroids can produce a “bland” form of cholestasis characterized by bile plugs in the liver without much inflammation. Other documented culprits include flucloxacillin, erythromycin, and trimethoprim/sulfamethoxazole.
Rare genetic conditions can also cause intrahepatic cholestasis from birth. These involve inherited defects in the very transport proteins that move bile acids across liver cell membranes. One form involves a faulty bile acid export pump, leading to bile acid accumulation and progressive liver damage. Another involves a defective protein responsible for getting protective fats into bile. Without those fats, raw bile acids damage the bile duct lining, sometimes severely enough to require a liver transplant in childhood.
What the Itching Feels Like
The defining symptom is pruritus, an intense, often maddening itch that typically has no visible skin changes. In pregnancy-related cholestasis, this usually starts after 30 weeks and tends to be worst on the palms of the hands and soles of the feet, though it can be widespread. The itching characteristically worsens at night, sometimes severely enough to disrupt sleep. Many people describe it as a deep, relentless sensation that doesn’t respond to typical anti-itch creams.
Jaundice, a yellowing of the skin and eyes, can develop but is less common and usually indicates more advanced bile buildup. Some people also notice dark urine and pale stools, which reflect the altered processing of bilirubin, a pigment normally excreted through bile.
How It Is Diagnosed
Diagnosis relies on blood tests. The most specific marker is the total serum bile acid level. Values above 10 micromol/L in the presence of itching are generally used to confirm intrahepatic cholestasis of pregnancy. Levels above 40 micromol/L are classified as severe and carry greater risk for complications.
Liver enzymes are usually elevated as well, with ALT values averaging around 148 IU/L and AST around 105 IU/L in large studies of ICP patients. These represent roughly 1.5 to 8 times the normal upper limit. Alkaline phosphatase also rises, though in pregnancy this can partly reflect normal placental production rather than liver damage alone. A predominantly direct (conjugated) bilirubin elevation, making up more than half the total bilirubin, points toward cholestasis rather than other liver conditions.
If there is any doubt about whether the obstruction is inside or outside the liver, an ultrasound can check the bile ducts. Normal-caliber ducts point to an intrahepatic cause. Dilated ducts suggest a blockage downstream, which may prompt further imaging.
Risks During Pregnancy
For the mother, ICP is uncomfortable but generally not dangerous to her liver long term. The real concern is fetal risk. Without management, ICP is associated with a 4 to 10-fold increase in stillbirth risk, and preterm birth rates are significantly higher: roughly 30% of ICP pregnancies deliver preterm compared to about 9% of unaffected pregnancies.
These risks are closely tied to bile acid levels. A large 2019 meta-analysis found that the risk of stillbirth is primarily elevated in women whose bile acid levels exceed 100 micromol/L. Below that threshold, especially with active monitoring and treatment, outcomes improve substantially. In fact, recent U.S. data showed that among women with diagnosed and managed ICP, stillbirth rates were actually lower than in the general population, likely because of the close surveillance and planned early delivery these patients receive.
Because of the dose-dependent relationship between bile acid levels and fetal risk, providers typically monitor bile acid levels throughout the remainder of pregnancy once a diagnosis is made. When levels reach above 40 micromol/L, planning for delivery before the due date becomes a more urgent consideration.
Treatment and What to Expect
The primary treatment for ICP is ursodiol, a medication that helps restore bile flow and lower circulating bile acid levels. It is typically started at a dose based on body weight and taken in divided doses throughout the day until delivery. Improvement in itching and liver test results can take 10 days or longer, and the dose may be gradually increased over several weeks if symptoms persist.
For drug-induced intrahepatic cholestasis, the most important step is stopping the offending medication. In most cases, bile flow normalizes and symptoms resolve over a period of weeks to months once the trigger is removed.
In pregnancy-related cholestasis, symptoms and abnormal lab values typically resolve within days to weeks after delivery, once hormone levels return to normal. However, ICP tends to recur in subsequent pregnancies, with recurrence rates that vary but are high enough that women who have experienced it once are usually monitored closely in future pregnancies. Women with ICP may also be more likely to develop cholestasis if they later take estrogen-containing contraceptives, since the underlying genetic susceptibility to hormone-triggered bile flow disruption remains.
When Cholestasis Is Not Pregnancy-Related
Outside of pregnancy, intrahepatic cholestasis can develop from a range of liver conditions including viral hepatitis, alcoholic liver disease, sepsis, and certain infiltrative diseases that affect liver tissue. The genetic forms, known as progressive familial intrahepatic cholestasis, typically present in infancy or early childhood and can progress to cirrhosis and liver failure without treatment.
Drug-induced cholestasis deserves special attention because it is both common and often overlooked. Antibiotics account for the largest share of cases. The cholestatic pattern of liver injury from amoxicillin/clavulanate can appear days to weeks after starting the medication and sometimes persists for months after discontinuation, a phenomenon called vanishing bile duct syndrome in severe cases. Anabolic steroids and oral contraceptives tend to cause a milder, more predictable form that resolves once the drug is stopped.
Regardless of the cause, the core problem is the same: bile acids that should be flowing into the intestines are instead circulating in the blood, causing itching, potential liver cell damage, and in the case of pregnancy, risk to the developing baby. Identifying and addressing the underlying trigger is the most effective path to resolution.